Age, comorbidity, treatment decision and prognosis in lung cancer
JAG Blanco, IS Toste, RF Alvarez… - Age and …, 2008 - academic.oup.com
JAG Blanco, IS Toste, RF Alvarez, GR Cuadrado, AM Gonzalvez, IJG Martín
Age and ageing, 2008•academic.oup.comDiscussion In this study, age and comorbidity played an important role in treatment
decisions in advanced NSCLC. Two population studies [9, 10] found that in advanced
stages, in the age group of 60–79 years, treatment was symptomatic in∼ 34–40% of
patients increasing to 52–65% in those aged 80 years or older as compared with 19–20% in
patients aged< 60 years. In these series, comorbidity also influenced therapeutic choice but
was less important than age. In our case both variables were correlated with the likelihood of …
decisions in advanced NSCLC. Two population studies [9, 10] found that in advanced
stages, in the age group of 60–79 years, treatment was symptomatic in∼ 34–40% of
patients increasing to 52–65% in those aged 80 years or older as compared with 19–20% in
patients aged< 60 years. In these series, comorbidity also influenced therapeutic choice but
was less important than age. In our case both variables were correlated with the likelihood of …
Discussion
In this study, age and comorbidity played an important role in treatment decisions in advanced NSCLC. Two population studies [9, 10] found that in advanced stages, in the age group of 60–79 years, treatment was symptomatic in∼ 34–40% of patients increasing to 52–65% in those aged 80 years or older as compared with 19–20% in patients aged< 60 years. In these series, comorbidity also influenced therapeutic choice but was less important than age. In our case both variables were correlated with the likelihood of receiving only BSC although the association was stronger with age.
Oxford University Press